

APERTURE HEALTH, INC.

Issuer's Updated Disclosure Obligations

Part A General Company Information

Item 1 The Name of the Issuer

The name of the issuer is Aperture Health, Inc. (the "Company".) The Company changed its name from flexSCAN, Inc. on February 28, 2008.

The Company is the surviving entity of a merger transaction with Triad Therapeutics, Inc., a Delaware corporation, which occurred on July 18, 2011.

Item 2 The Address of the Issuer's Principal Executive Offices

Triad Therapeutics, Inc
333A Route 46 West
Suite 130
Fairfield, NJ, 07004
www.triadtx.net

Item 3. The Jurisdiction and Date of the Issuer's Incorporation

Aperture Health, Inc., a Nevada corporation, was incorporated on February 13th, 2001.

Part B Share Structure

Item 4 The exact title and class of Securities outstanding.

Common Stock, Cusip# 03753T 208, Trading Symbol: "APRE"

Item 5 Par or stated value and description of the security.

Common Shares Par Value \$0.001 per share. Each outstanding share of Common Stock is entitled to one vote. Dividends are authorized by the Company's Board of Directors in accordance with Nevada law. Shareholders have no extraordinary material rights other than those authorized by law, and no provision in the issuer's bylaws or charter would delay, defer or prevent a change in control of the Company.

Item 6 Number of Securities Outstanding

- **Common Shares:** As of March 31, 2012, the Company had 150 million shares of Common Stock authorized with 42,525,954 shares outstanding, of which, 21,396,492 shares are outstanding as the "public float". There are 788 shareholders of record as of March 31, 2012.
- **Preferred Shares:** The Company is authorized to issue up to 10,000,000 shares of Preferred stock. As of March 31, 2012, no shares of Company Preferred Stock had been issued.

Item 7 Transfer Agent

The Company's transfer agent is Olde Monmouth Stock Transfer Co. Inc. ("Olde Monmouth"). Olde Monmouth is registered under the Exchange Act and is regulated by the Securities Exchange Commission. Olde Monmouth's contact information is:

Olde Monmouth Stock Transfer Co. Inc.
200 Memorial Parkway
Atlantic Highlands, NJ 07716
Phone: 732-872-2727
Fax: 732-872-2728
<http://www.oldemonmouth.com/>

Part C Business Information

Item 8 The nature of the issuer's business

A. Business Development

- 1) Form of Organization Aperture Health, Inc. ("the Company") is a corporation organized under the laws of the state of Nevada.
- 2) Year of Formation The Company was incorporated on February 13th, 2001.
- 3) Fiscal Year The Company's fiscal year ends on June 30th. The Company's sole operating entity, Triad Therapeutics, Inc has maintained a December 31st fiscal year since inception.
- 4) Bankruptcy Neither the Company, nor any of its predecessor entities has ever been in bankruptcy, receivership or any similar proceeding.
- 5) Material Reclassifications and Mergers On September 9, 2005, the Company, then called flexSCAN, Inc. ("flexSCAN"), effected a reverse merger with Fuel Corporation of America, Inc. ("FCA") where flexSCAN was the surviving entity. FCA was a Nevada Corporation. In March 2008, the Company's name was changed from flexSCAN, Inc. to Aperture Health, Inc. ("Aperture"). Triad Therapeutics, Inc. ("Triad") was incorporated in Delaware in 2007. On July 18, 2011, Triad merged into the Company via a reverse merger transaction.
- 6) Defaults on indebtedness The Company is in default on the following indebtedness:

- a. In May of 2006, Aperture entered into a 10% Promissory Note with Mr. Francis Pisano, a former executive with the Company, for the amount of \$35,000. The Note matured on August 4th, 2008 and the Company has been in default on the Note with no payments being made. In accordance with the reverse merger agreement, Triad has assumed \$25,000 of the outstanding debt to Mr. Pisano. Subsequent to this, Mr. Pisano has executed an Agreement between Mr. Robert Rubin, Mrs. Miriam Gold, and the Corporate Communications Group, Inc. to purchase the Note in its entirety. The Note Assignment Agreements and Conversion Agreements are posted on Aperture's OTC site under Legal Opinion and Conversion Notes posted on 12/23/11. On December 5th, 2011, the Company entered into a Note Conversion Agreements between Corporate Communications Group, Inc., Robert Rubin and Miriam Gold, for the ability to convert all of the \$25,000.00 principal outstanding debt on the note to 25,000,000 shares of free trading common stock of the Company.
- b. On April 24, 2009, Triad issued ten notes to its principal lenders with a total face amount of \$834,217.00. The notes matured on March 1, 2010. As of March 31st, 2012, Triad has not made any payments on the Notes.
- c. On November 18th, 2010, Triad issued ten additional Notes to the same lenders with a face amount of \$148,000.00. The notes matured on October 31st, 2011. As of March 31st, 2012, Triad has not made any payments on the Notes.
- d. On May 31, 2011, Triad issued a note to Visual Displays, Inc. with a face amount of \$100,000. The notes matured on September 30th, 2011. As of March 31, 2012, Triad has paid back \$50,000 of the outstanding liability to Visual Displays, Inc.
- e. Triad Therapeutics remains in arrears with respect to payroll tax payments, penalties and interest assessed thereon for both Federal and New Jersey State Trust Funds. Federal liens and levies have been executed on certain corporate bank accounts and some contracted payers for receivables. Management has been in communication with both I.R.S. and New Jersey State agents regarding Triad's outstanding tax debt, with the intent to have all amounts paid and current by entering into a payment arrangement together with a substantial down-payment, with the proceeds from additional corporate funding. As of March 31, 2012, the Company remains in arrears for approximately 341,000.00 in Federal 941 taxes, New Jersey withholding and New Jersey labor workforce taxes, and penalties and interest.
- f. In December of 2010, Triad issued a Promissory Loan Agreement to Mr. Louis Juliano with a face amount of \$30,000 plus interest. As of March 31, 2012, Triad has not made any payments back to Mr. Juliano.
- g. Aperture intends to recognize any individual or corporate outstanding debt relating to past loans and debentures for accounting purposes as required under U.S.GAAP. Further, the Merger Agreement by and between Aperture Health, Inc. and Triad Therapeutics, Inc., contemplated that there shall be no greater than \$25,000.00 of existing Aperture debt post merger as a legal

and binding liability assumed by the post merger Company. Notwithstanding the foregoing, the current Board of Directors and Management of Aperture Health, Inc. and the Company's wholly owned subsidiary, Triad Therapeutics, Inc., will in its sole discretion, evaluate and reorganize and/or resolve in a commercially reasonable manner, the prior existing debt recognized for accounting purposes only. Resolution may mean the following, including without limitation, forgiveness of debt or conversion of debt to common stock. As of the merger date, Aperture had outstanding Note obligations of \$1,275,000 as reflected in the September 2011, Consolidated Financials posted on the Company's OTC site and in the December, 2011 Consolidated Financial Data attached to this Disclosure Document. As of March 31, 2012, the balance owed on the Aperture Notes is \$1,250,000.00 which accounts for the \$25,000.00 conversion of the "Pisano" Note detailed in "a" above.

- h. On Aug. 10, 2011, Triad issued a promissory note to Brigadier Investment Group, maturing 12/31/2011, with Triad being obligated to pay a total of \$60,000.00 (a \$50,000.00 note plus a \$10,000.00 origination fee). In addition, Triad entered into a short term consulting agreement with Brigadier, whereby Triad agreed to pay \$ 40,000.00 for various services through 12/31/2011. As of March 31, 2012, Triad has paid back \$50,000.00 of the outstanding liability and remains in default of the terms of the Note owing another \$50,000.00. Copies of both the Note and Consulting Agreement are posted in Aperture's OTC Financial Section.
- i. On December 15th, 2011, Aperture issued a Promissory Note to McLain Amarillo III, LLC, maturing on February 15th, 2012 with Aperture being obligated to pay a total of \$120,000.00 (a \$100,000.00 Note plus a \$20,000.00 origination fee). The obligation is in default as of February 15th, 2012. Aperture also entered into a short term Consulting Agreement with McLain Amarillo III, LLC whereby Aperture agreed to pay \$80,000 for various consulting services through 06/30/2012. Copies of both the Note and Consulting Agreement are posted in Aperture's OTC Financial Section.

- 7) Change of Control In connection with the reverse merger of Triad into the Company, the Triad Shareholders received a controlling interest in the Company. Certificates of merger have been obtained from the Nevada and Delaware Secretaries of State.
- 8) Increase of 10% or more of the same class of outstanding equity securities: In September of 2011, the Company issued 21 million new common shares to executive management, various employees and outside individuals and entities as consideration for services rendered. In December of 2011, the Company issued 5,050,000 new common shares in relation to the "Pisano" Promissory Note conversion detailed above in #6a (defaults on indebtedness). From January 1, 2012 through March 31, 2012, the Company issued an additional 16,313,000 new common shares in relation to the "Pisano" Promissory Note conversion detailed above in Section 6(a).

- 9) Stock Splits On September 13, 2011, the Company executed a 1:500 reverse stock split. The Company does not anticipate any future stock splits or dividend payments.
- 10) Delisting The Company has never had any securities delisted or deleted from any exchange.
- 11) Material Legal Proceedings The Company is involved in the following legal proceedings:
 - a. The Company is indebted to the United States Treasury and the State of New Jersey for approximately \$341,000.00, including penalties and interest as of March 31, 2011. Federal Tax Liens and Levies have attached to Triad's corporate bank accounts and receivables. Executive Management have been in communication with both IRS and NJ State agents regarding the company's outstanding tax debt with the intent to have all amounts paid and current with a portion of the proceeds from Aperture Health's further investor funding.
 - b. Integrated Medical Systems, a vendor of IV therapy supplies and pump rentals, has sued Triad for unpaid invoices totaling \$144,127.83. In Feb, 2012, a Default Judgment was entered against Triad.
 - c. A Judgment for \$5,000 was placed against Triad in NJ for a lawsuit by Medical Specialties, Inc., a vendor of IV supplies to Triad.
 - d. PromptCare, Inc., New Jersey-based home IV therapy company, has sued the Company alleging violation of a non-compete agreement between Promptcare and a former employee. The Company has agreed to pay \$20,000 to settle this matter. Triad has paid \$3,000.00 on this outstanding liability, owing another \$17,000.00
 - e. Professional Home Infusion- an IV Nursing services vendor totaling \$2,687.50
 - f. Impulse Courier has sued Triad for outstanding invoices totaling \$2592

B. Business of Issuer

Neither Aperture Health, Inc. nor Triad Therapeutics, Inc. have been a "shell company." Aperture Health, Inc. is the sole owner of Triad Therapeutics, Inc.

The Company participates in both Federal and State healthcare reimbursement programs (Medicare and Medicaid) and is subject to changes (both positive and negative) in reimbursement or coverage from these sources. The Company is considered a medical waste generator in New Jersey by virtue of dispensing needles and syringes for patient use at home and therefore it does incur some expense in providing "sharps" containers to clients in the home and upon therapy completion, picking up and having the medical waste disposed of through contracted waste management services. The costs of this process are reflected in the company's financial data.

The Company does not have any expenses relating to research and development activities.

As of March 31st, 2012, The Company has six full time employees.

Item 9. The nature of services offered

Triad provides specialized home healthcare services to patients requiring intravenous therapy including antibiotics, pain management, hydration, immunoglobulins, steroids, total nutritional solutions, and IV catheter insertions and maintenance. The Company provides a complete solution to patients including the preparation and delivery of sterile compounded IV medications, supplies and equipment, along with specialized nursing care and teaching of the patient and/or caregivers on the administration of therapies as prescribed by a physician.

Triad is a fully accredited home IV therapy company, achieving this “gold standard” status in 2007. The company has built a well respected reputation in its industry for its therapy expertise and commitment to care for its patient clients. The company services clients throughout the States of New Jersey, New York and Connecticut, providing opportunity for organic growth. Triad full time marketing and sales personnel continuously represent the company in the core services areas, growing and maintaining the company’s referral source base. Patient referrals are made from physicians, hospitals, insurance companies, veterinarians and hospice care providers that have established a professional rapport with Triad.

All patient clients accepted to Triad’s service have been preapproved for care by the client’s health insurance provider. Triad maintains numerous managed care service provider contracts, many of which are part of “closed networks”, thus provide strong barriers to entry in the industry.

The business of home infusion therapy is a mature industry with multiple competitors. The company markets its services to hospital discharge planners, physicians, hospice providers, and veterinarian hospitals. The company competes for client referrals by providing enhanced customer service and reliable cross communication with the patients care givers, nurses, pharmacists and physicians.

Item 10 The nature of the Company’s facilities

The Company leases a 9,000 square foot facility in northern New Jersey. The facility contains a fully licensed, equipped and JCAHO accredited pharmacy along with complete client intake, insurance billing and receivables management services. Under the terms of the current lease, which expires in July, 2012, the Company pays \$10,833.33 in monthly rent. The Company remains in arrears with respect to the rent owed and management continues to negotiate with the facility management company to bring the outstanding balance current.

PART D Management Structure and Financial Information

Item 11 The name of the Chief Executive Officer, members of the Board of Directors and control persons.

Aperture Health, Inc.'s President, CEO, Chairman and Pharmacist-in-Charge is James E. Hennig, R.Ph. Mr. Hennig is a New Jersey Registered Pharmacist with over 25 years of home IV therapy industry experience. His responsibilities have included business development, sales and marketing, clinical operations, middle and executive management roles for public and private healthcare companies ranging from \$5M to \$100M in revenues. Mr. Hennig maintains his office location at the corporate offices of Aperture Health, Inc., 333A Route 46 West, Suite 130, Fairfield, NJ 07004. For his services to the company, the Company pays Mr. Hennig an annual salary of \$180,000. As of March 31, 2012, Mr. Hennig owns 10,000,000 shares of Company Common Stock.

Mr. Arnold Silver is a member of the Board of Directors of Aperture Health, Inc. Mr. Silver's brings strength to Aperture's Board from his 27 years of experience in the ownership/operations of multiple restaurant enterprises.

Mr. Lance Friedman is the Company's secretary and a member of the Company's Board of Directors. Mr. Friedman was most recently a partner in Cooper Beech Equity and Corinthian Holdings, both Merchant Banking firms. He previously served as Managing Director/Partner of EGL Holdings, Inc., a venture capital and boutique investment banking concern in charge of healthcare practice and investments. Mr. Friedman has served in executive operational capacities for various companies including Wireless MD, M2Verticom, Brooklyn Bottling and Canning Corp, and Fletcher-Flora Health care Systems. He holds a BA from American University and a JD from Benjamin Cardozo School of Law, Yeshiva University. Mr. Friedman owns 3,000,000 shares of Company common stock.

Mr. Larry Friedman serves as Aperture Health's Treasurer and is a member of the Company's Board of Directors. Mr. Friedman has maintained Triad's unaudited financial records since inception in 2007. He holds a BS in Accountancy from NYU in 1954 and a State of NY CPA since 1964. Mr. Friedman managed several public accounting firms from 1966 through 1988. Since, retiring in 1988, Mr. Friedman performed forensic accounting services on a contract basis.

To The Company's knowledge there are no active past, current and/or pending legal or disciplinary histories associated with any of the aforementioned individuals that would prevent them from fulfilling their duties on behalf of the Company.

Triad has engaged in the following Related Party Transaction: In December 2010, Triad entered into a Promissory Loan Agreement with Mr. Louis Juliano totaling \$30,000 plus interest. Mr. Juliano is the father of Serena Juliano, an employee and stockholder of Aperture Health, Inc.

There are no Conflict of Interest issues to report.

Items 12 & 13 Financial information for the most recent and 2 preceding fiscal years.

Unaudited financial results for the company's prior periods are posted on the company's OTC site under the financial section and identified as "preliminary results", "interim financial report" and "quarterly report".

Unaudited Financial Results for the Quarter ended March 31, 2012 are attached to the end of this Updated Disclosure Document.

Item 14 Beneficial Owners.

As of March 31st, 2012, the following are the owners of more than 5% of Aperture Health's stock:

James Hennig, the company's CEO/President owns 10,000,000 shares of Company Common Stock.

Lance Friedman owns 3,000,000 shares of Company Common Stock. Mr. Friedman is the secretary for the Company and a member of the Board of Directors. . Mr. Friedman has provided advice to Triad Therapeutics since its formation.

The above individuals may be contacted care of the Company at 333A Route 46 West, Suite 130, Fairfield, NJ 07004. Tel# (973)-244-0044.

Gersten -Savage LLP owns 4 Million common shares. Located at 600 Lexington Ave, 9th Floor, New York, NY 10022 (212)- 752-9700, the firm has provided legal services relating to Triad and Aperture's reverse merger and other corporate matters.

Item 15 Outside providers that advise the issuer on matters relating to operations, business development and disclosure.

Counsel: Gersten-Savage, LLP (address and contact listed above)

Auditor: Aperture/Triad has utilized the services of Mr. Larry Friedman (detailed above) for all accounting needs including payables management, tax filings and unaudited financial reports.

The Company has engaged the auditing firm of EFP Rotenberg, LLP to prepare audited financial statements for the Company. The primary accountant at EFP Rotenberg working with Aperture is Mr. Nick Bottini and is available at 585-427-8900 with corporate offices at 280 Kenneth Drive, Suite 100, Rochester, NY 14623

Investor Relations Consultant: Incubus Capital, LLC., 3233 Philip Ave, NY, NY 10465

Item 16 Management's discussion and analysis of financial condition and results of operations.

Triad Therapeutics, Inc., was formed in 2007 after careful planning and commitments made to ensure effective capitalization for the company of \$1.8 million within the first 12 months of

organizing. Negative developments within the investment banking community associated with the downturn in the US economy caused, and continue to induce, a downward pressure on the company's ability to aggressively market services and expand operations due to the company only being able to obtain \$1.4 million over 4.5 years. The high cost of starting and maintaining a hi-tech IV therapy pharmacy business in a highly competitive industry, coupled with industry-standard delays in reimbursement through insurance payers, make it imperative that a substantial stream of capitalization is available for the Company to achieve a "break even" point quickly with sustained profitability quickly thereafter.

Attached to this the end of this Quarterly Updated Disclosure Document are the March 31, 2012 Quarterly Financial Results. The Company recorded revenue of \$119,652.02 with losses of (\$334,076.86). The company continues to post lower revenue and higher losses, primarily due to management's need to curtail the company's marketing and business development activities while it continues to focus on raising the capital requirements for the company to remain a going concern.

The Company has no Off-Balance Sheet arrangements.

Part E. Issuance History

Item 17 List of Securities Offerings and Shares Issued for Services.

The Company has not engaged in any securities offerings in the last two years.

In connection with the July 18th, 2011 reverse merger of Triad into the Company, the Company issued 21 million restricted common shares to certain employees and service providers for services provided to the Company. The majority recipients are listed in the Beneficial Owners Section, above.

In connection with the Pisano Note conversion (detailed in Sect 6(a) above), the Company, on various dates since 12/14/11, issued a total of 21,363,000 free trading shares with an additional 3,637,000 remaining to be issued as requested by the principals who acquired the note. Copies of the Legal Opinion and Conversion Documents are posted on the APRE OTC site under the financial tab with a publish date of December 23, 2011 labeled as "Legal Opinion and Conversion Notes".

Part F. Exhibits

Item 18 Material Contracts

In its normal course of business, the Company enters into contracts for entry into insurance provider networks, supply purchases, and nursing services.

All Agreements and Notes disclosed in Section A #6 (defaults on indebtedness) above are posted on the Company's OTC site in the financial section.

Item 19 Articles of Incorporation and Bylaws

Please see Aperture Health's Articles of Incorporation and Bylaws filed under separate postings on the OTC Disclosure Service. No changes or amendments to the Articles or Bylaws have occurred that have not been previously reported.

Item 20 Purchases of Equity Securities by the Issuer


The Company has not purchased shares or other units of any class of its own equity securities, nor has any affiliated purchaser on the Company's behalf.

Item 21 Issuer's Certifications

I, James E. Hennig, Chief Executive Officer of Aperture Health, Inc. certify that:

1. I have reviewed this supplemental information statement of Aperture Health, Inc., a Nevada Corporation.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which statements were made, not misleading with respect to the period covered by this disclosure statement, and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in the disclosure statement.

Date: May 15, 2012



By: James E. Hennig, R.Ph., President/CEO

Aperture Health, Inc.

Aperture Health, Inc.

Consolidated Statement of Operations

For the Quarter Ended March 31, 2012

Unaudited

Revenue	\$	119,652.02
Cost of goods sold		72,920.61
Gross Profit		46,731.41
Administrative expenses		358,875.04
Interest and finance expenses		21,933.23
Income before income taxes		(334,076.86)
Income tax expense		-
Net Income		(334,076.86)

Aperture Health, Inc.

Consolidated Balance Sheet

For the Quarter Ended March 31, 2012

Unaudited

Assets:

Cash	\$	195.81
Accounts receivable		102,134.22
Prepaid and other current assets		63,227.58
Total current assets		165,557.61
Fixed assets		11,182.97
Security deposits		30,000.00
Intangible assets		52,003.14
Total assets		258,743.72

Liabilities:

Accounts payable	580,860.57
Due to officer	69,548.08
Notes payable	1,474,367.32
Accrued expenses	206,474.16
Payroll tax liabilities	275,210.89
Other current liabilities	258,065.73
Total current liabilities	2,864,526.75
Long term notes payable to shareholders	1,248,998.00
Total liabilities	4,113,524.75

Shareholders' equity

Common stock, par value	42,525.95
Additional paid in capital	136,474.05
Accumulated deficit	(4,033,781.03)
Total shareholder's equity	(3,854,781.03)
Total liabilities and shareholders' equity	258,743.72

Aperture Health, Inc.
Consolidated Statement of Cash Flows
For the Quarter Ended March 31, 2012
Unaudited

Cash provided (used for):	
Operating activities:	
Net income for the period	\$ (334,076.86)
Depreciation and amortization	5,549.39
Changes in non-cash working capital:	
Accounts receivable	29,538.14
Prepaid and other current assets	8,649.44
Accounts payable	28,963.99
Due to officer	6,208.04
Accrued expenses	16,447.02
Payroll tax liabilities	30,351.11
Other current liabilities	6,630.25
Net cash provided by (used in) operating activities	(201,739.48)
Investing activities:	
Fixed Assets: Computer Hardware	(2,030.46)
Acquisition related costs	725.00
Net cash used in Investing activities	(1,305.46)
Financing activities	
Borrowing (repayments) pursuant to notes payable	199,976.88
Net cash provided by financing activities	199,976.88
Net increase (decrease) in cash and cash equivalents	(3,068.06)
Cash and cash equivalents beginning of period	3,263.87
Cash and cash equivalents end of period	\$ 195.81

Aperture Health, Inc.

Consolidated Statement of Shareholders' Equity
For the Quarter Ended March 31, 2012
Unaudited

	Common Stock		Additional		Total	
	Shares	Amount	Paid In Capital	Accumulated Deficit	Shareholders' Equity	Equity
Balance as of December 31, 2010	26,050,631	26,050.63	127,949.37	(2,999,444.39)	(2,845,444.39)	(2,845,444.39)
Share issuance pursuant to recapitalization	162,323	162.32	(162.32)		-	-
Net loss for year 2011				(700,259.78)	(700,259.78)	(700,259.78)
Issuance of shares	16,313,000	16,313.00	8,687.00		25,000.00	25,000.00
Net loss for Quarter ended March 31, 2012				(334,076.86)	(334,076.86)	(334,076.86)
Balance as of March 31, 2012	42,525,954	42,525.95	136,474.05	(4,033,781.03)	(3,854,781.03)	(3,854,781.03)

APERTURE HEALTH, INC.

Notes to Unaudited Consolidated Financial Statements

03/31/2012

Note 1: Organization – Business Activities

Aperture Health Inc. (The Company), a Nevada Corporation, was incorporated on Sept. 08, 2005. On July 18, 2011, Triad Therapeutics Inc. (Triad) merged into The Company via a reverse merger transaction as consideration for all of the issued and outstanding shares of Triad. The Triad shareholders received a 51% controlling interest in The Company. On Sept. 13, 2011, The Company executed a 1 : 500 reverse stock split. Triad is the sole operating entity. Triad was incorporated in Delaware in 2007.

The Company's primary line of business is providing Home intravenous therapy services to patients requiring specialized intravenous medication and nursing services. Triad promotes these services throughout the states of New Jersey, New York and Connecticut.

Note 2: Basis of Presentation:

The Consolidated Financial data contained herein represent Triad as the operating company, as Aperture Health had no operations during this period.

The Consolidated Financial information at Mar. 31, 2012 is unaudited but includes all adjustments (consisting only of normal recurring adjustments) which, in the opinion of management, are necessary to state fairly the consolidated financial information set forth therein, in accordance with generally accepted accounting principles.

The acquisition of Triad by the Company was accounted for by a reverse merger, whereby Triad is the continuing entity for financial reporting purposes and is deemed, for accounting purposes, to be the acquirer of the Company. In accordance with the applicable accounting guidance for accounting for the business combination as a reverse merger, Triad is deemed to have undergone a recapitalization, whereby Triad is deemed to have issued equity to the Company's common stock holders. Accordingly, although the Company, as Triad's legal parent company, was deemed to have legally acquired Triad, in accordance with the applicable accounting guidance for accounting for the transaction as a reverse merger and recapitalization, Triad is the surviving entity for accounting purposes and its assets and liabilities are recorded at their historical carrying amounts with no goodwill or other intangible assets recorded as a result of the accounting merger with the Company. All intercompany balances and transactions have been eliminated upon consolidation.

Note 3: Property and Equipment:

Property and Equipment are stated at cost. Depreciation is computed utilizing the straight line method over the life term of the asset in accordance with IRS guidelines for asset life. Repairs and maintenance are charged to expense as incurred, while betterments and renewals are capitalized. The cost of fixed assets and the related accumulated depreciation are removed from the account upon retirement or disposal, with any gain or loss being recorded in operations.

Note 4: Intangible Assets:

Pre-operating expenses are recorded at cost and are amortized using the straight line method over their estimated life of 15 years in accordance with IRS guidelines.

Note 5: Notes Payable:

a). On Dec. 20, 2010, Triad issued a promissory note to Mr. L. Juliano with a face amount of \$30,000.00 plus interest at 5% per annum. Triad has been in default according to the repayment terms of the loan.

b). On May 31, 2011, Triad issued a promissory note to Visual Displays Inc., with a face value \$50,000.00, maturing 09/30/2011 with Triad being obligated to pay a total of \$100,000.00 (the \$50,000.00 note plus a \$50,000.00 loan origination fee). The obligation is currently in default. The balance as of March 31, 2012 is \$65,000.00.

c). On Aug. 10, 2011, Triad issued a promissory note to Brigadier Investment Group, maturing 12/31/2011, with Triad being obligated to pay a total of \$60,000.00 (a \$50,000.00 note plus a \$10,000.00 origination fee). The obligation is currently in default. As of March 31, 2012, \$50,000.00 has been paid.

Triad also entered into a short term consulting agreement with Brigadier, whereby Triad agreed to pay \$40,000.00 for various services through 12/31/2011.

d). As of the merger date, Aperture had outstanding note obligations of \$1,275,000.00. The Company issued 25,000,000 free trading common shares at par value in consideration for \$25,000.00 of one of the notes. The current balance of the notes total \$1,250,000.00.

e). On Dec. 15, 2011, Aperture issued a promissory note to McLain Amarillo III LLC, maturing 02/15/2012, with Aperture being obligated to pay a total of \$120,000.00 (a \$100,000.00 note plus a \$20,000.00 origination fee). The obligation is currently in default.

Aperture also entered into a short term consulting agreement with McLain Amarillo III LLC, whereby Aperture agreed to pay \$80,000.00 for various services through 06/30/2012.

Note 6: Taxes:

Triad remains in arrears with respect to payroll tax payments for Federal and New Jersey and penalties and interest assessed thereon. Federal liens and levies have been executed on certain corporate bank accounts and some contracted payers for receivables. Management has been in communication with both the I.R.S. and New Jersey State agents regarding Triad's outstanding tax debt, with the intent to have all amounts paid and current, by entering into a payment arrangement, together with a substantial down-payment via additional funding from the Company's majority debt holders.

Note 7: Litigation:

- a). Triad is currently involved in litigation with several vendors. Management expects to have all litigation resolved by September, 2012.
- b). Triad has been sued, alleging a violation of a non-compete agreement re a current Triad employee and former employer. Triad has agreed to pay \$20,000.00 in settlement, payable with \$10,000.00 due 11/01/2011 and \$10,000.00 due on 02/01/2012. The obligation is currently in default. As of March 31, 2012, Triad has paid \$3,000.00 towards this settlement.

Note 8: Leasehold:

Triad leases 9,000-sq feet of office and a fully licensed equipped and JACHO accredited pharmacy at a monthly rental of \$ 10,833.33 plus CAM and its portion of real estate taxes and any yearly CAM increases. Triad is currently in arrears in lease payments. Management continues to negotiate a payout arrangement with landlord in bringing the lease obligation current. The current Lease expires July 31, 2012.

Note 9: bad Debt Write off:

During the first quarter of 2012, the Company received notification that Infusion Solutions Inc. filed for Chapter 7 Bankruptcy on April 20th, 2012. The Company has recorded a Bad debt in the amount of \$23,136.78 .

Note 10: Going Concern Disclaimer

The Company is currently dependent upon raising capital to supplement working capital deficiencies. If the company is not successful in raising additional working capital, the Company may not be able to continue its operations in the normal course of business nor meet its obligations.